On Monday, BridgeBio Pharma Inc (NASDAQ: BBIO) was 3.42% up from the session before settling in for the closing price of $39.78. A 52-week range for BBIO has been $21.62 – $40.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 40.48% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -2.22%. With a float of $160.74 million, this company’s outstanding shares have now reached $189.83 million.
In an organization with 730 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.95%, operating margin of -547.57%, and the pretax margin is -528.55%.
BridgeBio Pharma Inc (BBIO) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward BridgeBio Pharma Inc stocks. The insider ownership of BridgeBio Pharma Inc is 15.35%, while institutional ownership is 85.69%. The most recent insider transaction that took place on Jun 10 ’25, was worth 171,680. In this transaction Director of this company sold 4,292 shares at a rate of $40.00, taking the stock ownership to the 1,764 shares. Before that another transaction happened on Jun 10 ’25, when Company’s Director proposed sale 4,292 for $40.00, making the entire transaction worth $171,680.
BridgeBio Pharma Inc (BBIO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -2.22% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
You can see what BridgeBio Pharma Inc (BBIO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 61.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.53, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -1.58 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Let’s dig in a bit further. During the last 5-days, its volume was 2.44 million. That was inferior than the volume of 3.01 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 90.19%. Additionally, its Average True Range was 1.47.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 98.35%, which indicates a significant increase from 97.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.28% in the past 14 days, which was lower than the 52.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.35, while its 200-day Moving Average is $30.84. However, in the short run, BridgeBio Pharma Inc’s stock first resistance to watch stands at $41.79. Second resistance stands at $42.43. The third major resistance level sits at $43.51. If the price goes on to break the first support level at $40.06, it is likely to go to the next support level at $38.98. The third support level lies at $38.34 if the price breaches the second support level.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
There are 189,881K outstanding shares of the company, which has a market capitalization of 7.81 billion. As of now, sales total 221,900 K while income totals -535,760 K. Its latest quarter income was 116,630 K while its last quarter net income were -167,420 K.
